Immunotherapy
Finding ways to stimulate the body's immune system to help attack cancer cells is a growing area of research at The Institute of Cancer Research.
Clinical trials led by the ICR and our hospital partner The Royal Marsden have shown that the immunotherapy drug pembrolizumab can help extend the lives of some patients with advanced head and neck cancer, and prostate cancer.
The use of 'oncolytic' viruses, which can kill cancer cells both directly and by directing the immune system against them, is also an exciting area of research being explored by ICR researchers.
This page highlights recent news stories, blog posts and videos that concern immunotherapy research at the ICR.
Related pages
Latest ICR News
-being-attacked-by-two-cytotoxic-t-cells-(red)-547x410.tmb-hbmobile.png?Culture=en&sfvrsn=8f59440b_2 "Immunotherapy - Oral squamous cancer cell (white) being attacked by two cytotoxic T cells (red) 547x410")
Immunotherapy gives head and neck cancer patients extra years disease free
An immunotherapy treatment helps patients live years longer without their cancer getting worse or coming back, a major phase III trial has found.
Molecular profiling is key to better outcomes for young adults with brain cancer, study shows
A recent study on an aggressive type of brain cancer has significantly advanced the understanding of the spectrum of tumours that occur in teenagers and young adults (TYA).